We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Drug Targets – Products

1.2 GHz NMR Installation.
Product News

Bruker Announces First 1.2 GHz NMR Installation in the United States

Novel GHz-class NMR systems are enabling unprecedented life science and materials research in functional structural biology, drug discovery, metabolomics and cleantech
research.
Compendium

Developments in Drug Discovery & Targeting

Download this compendium to learn more about developments in high-throughput screening, target-based drug discovery and fragment-based drug discovery.
Engaging in research is like participating in a high-stakes poker match.
Product
Advertisement

Don't Gamble With Your Research: The Winning Hand of Label-Free Protein Characterization

Engaging in research is like participating in a high-stakes poker match. The potential reward? The discovery of the next blockbuster drug. The gamble? Risking billions on a molecule that doesn't pay off. In this game, the winning hand lies in the tools that can identify the most promising leads.
Determine Kinetics Earlier in the Drug Discovery Process
App Note / Case Study

Determine Kinetics Earlier in the Drug Discovery Process

This app note highlights how reliable kinetics and affinity for high-affinity interactions can be obtained from significantly less data than is commonly used.
Bio-Rad Anti-dupilumab Antibodies.
Product News

Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development

Range of highly selective anti-idiotypic antibodies now includes six antibodies specific to dupilumab and its biosimilars for bioanalysis and Drug Monitoring.
Drug Kinetics SPR
Compendium

Optimize Your Affinity and Kinetics Data Analysis

Accurate kinetics and affinity data is essential for predicting the efficacy of novel therapeutics and for making quick decisions about weak candidates. However, analysis methods that require labelling can cause steric interference and influence data outcomes.
Sygnature Discovery logo.
Product News

Sygnature Discovery Launches Its LPS In Vivo Model To Profile Early-Stage Anti-Inflammatory Drugs

Sygnature Discovery has established an in vivo LPS model of inflammation which can help understand life-limiting neuroinflammatory conditions like Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and traumatic brain injuries and identify new drug targets.
Assess Small Molecule Kinetics and Affinity in Just One Step - image
App Note / Case Study

Assess Small Molecule Kinetics and Affinity in Just One Step

This application note demonstrates how reliable kinetics and affinity can be obtained from single measurement data, increasing sample throughput and saving sample material.
Scientists working with assays
Compendium

Achieve Successful BLI and SPR Assays

Designing and performing assays that accurately measure the binding kinetics of biomolecular interactions requires highly technical skills. Hence, such methods can feel out of reach for many scientists.
Successful BLI
Product
Advertisement

Good Data. Rich Insights. More Discoveries.

Label-free biosensor technologies have emerged as a promising approach to identify high-value hits with a strong likelihood of success as a therapeutic. Unlike traditional approaches of drug discovery, they are fast, sensitive, and come with improved success rates towards high-value drug candidates.
Advertisement